Recurrence After Gastric and Intestinal Polyp Resection (RAGIP)

Lanzhou University

Status: Not yet enrolling

Conditions: Adenomatous Polyps; Colorectal Adenoma; Colon Polyps; Intestinal Polyps; Gastric Polyps; Gastric Adenoma and Early Gastric Cancer; Colorectal Polyps

Study type: Observational

Funder types: Other

Identifiers

NCT07314554

LDYYczf2025121801

Details and patient eligibility

About

This is a retrospective and prospective cohort study designed to evaluate the recurrence rate and identify risk factors after endoscopic resection of gastric and intestinal polyps.

BACKGROUND: Gastric and intestinal polyps are common digestive diseases with potential for malignant transformation. Although endoscopic resection is the standard treatment, recurrence rates range from 10-50%, and the mechanisms and risk factors remain unclear.

OBJECTIVES:

Primary: To assess short-term (1-year) and long-term (3-year) recurrence rates after endoscopic polyp resection Secondary: To identify independent risk factors and develop a recurrence risk prediction model

DESIGN: Mixed retrospective-prospective cohort study

• Retrospective cohort: Patients who underwent polyp resection from 2021-2022, with follow-up data through 2024
• Prospective cohort: Patients enrolled from 2024-2025, with standardized follow-up through 2028

SETTING: Single tertiary referral center with >10,000 endoscopic polyp resections performed since 2021

PARTICIPANTS: Approximately 1,600-1,800 adult patients (≥18 years) who underwent complete endoscopic resection of gastric or intestinal polyps

FOLLOW-UP:

• Short-term: 1 year post-resection (±2 months)
• Long-term: 3 years post-resection (±3 months)

MAIN OUTCOME: Recurrence rate defined as new polyp detection at original or different sites during endoscopic surveillance

POTENTIAL RISK FACTORS: Patient demographics, polyp characteristics (size, number, location, pathology), resection method, Helicobacter pylori status, lifestyle factors, and medication use

EXPECTED IMPACT: Results will inform personalized surveillance strategies and optimize resource allocation for post-polypectomy follow-up.

Enrollment: 2,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18 years or older
• First-time endoscopic examination (gastroscopy or colonoscopy) at the study center
• Pathologically confirmed polyp of any type (adenomatous, hyperplastic, inflammatory, fundic gland polyp, hamartomatous, serrated lesion)
• Complete endoscopic resection performed (including EMR, ESD, snare polypectomy, hot biopsy forceps, or argon plasma coagulation)
• Negative resection margins or complete resection assessed by pathology
• At least one follow-up endoscopic examination completed (for retrospective cohort) or willingness to complete follow-up (for prospective cohort)
• Complete baseline clinical data available

Exclusion criteria

• Hereditary polyposis syndromes (familial adenomatous polyposis, Lynch syndrome, Peutz-Jeghers syndrome, juvenile polyposis syndrome)
• Inflammatory bowel disease (ulcerative colitis or Crohn's disease)
• Previous history of gastric or colorectal cancer
• Cancer detected at initial resection (stage T1b or higher)
• Non-polyp pathology (e.g., submucosal tumors, normal mucosa)
• Incomplete resection with positive margins that were not re-treated
• Lost to follow-up with no available surveillance data (for retrospective cohort)
• Pregnancy at time of enrollment
• Inability or unwillingness to provide informed consent (for prospective cohort)

Trial design

2,000 participants in 2 patient groups

Retrospective Cohort

Description:

Patients who underwent endoscopic polyp resection from January 2021 to December 2022, with retrospective data collection and follow-up through December 2025

Prospective Cohort

Description:

Patients undergoing endoscopic polyp resection from October 2024 to December 2025, with prospective standardized data collection and follow-up through December 2028